BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...to submit an NDA to FDA next quarter seeking Xpovio's approval in the indication; the XPO1...
...– T cell immunoreceptor with Ig and ITIM domainsXPO1 (CRM1) – Nuclear export (SINE) protein exportin 1 Danielle...
...Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm Therapeutics Inc. Aurinia Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Astellas Pharma Inc. Janus kinase (JAK) Exportin 1 (XPO1) (CRM1)...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...to treat relapsed or refractory diffuse large B cell lymphoma. The company said the oral XPO1...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...second-line or later multiple myeloma patients (HR=0.70; p=0.0075). Karyopharm has submitted an sNDA for the XPO1...
...PD-1 (PDCD1; CD279) - Programmed cell death 1 RET - Ret proto-oncogene XPO1 (CRM1) - Exportin 1 BioCentury...
...Therapeutics Inc. MacroGenics Inc. Arvinas Inc. Blueprint Medicines Corp. Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Ret proto-oncogene (RET) Exportin 1 (XPO1) (CRM1) Lymphocyte-activation...
BioCentury | May 4, 2020
Deals

Stemline takeout gives Menarini U.S. oncology beachhead

...chronic myelomonocytic leukemia, myelofibrosis, multiple myeloma and acute myelogenous leukemia (AML). Stemline is also developing XPO1...
...Epidermal growth factor receptor 2 PI3K - Phosphoinositide 3-kinase PIM1 - Pim-1 XPO1 (CRM1) - Exportin 1 Paul...
BioCentury | Apr 8, 2020
Deals

COVID-19 roundup: U.S. to freeze WHO funding as Wellcome calls on CEOs to support $8B fund; plus Ridgeback-Emory, Karyopharm, IQVia and more

...a global trial of Xpovio selinexor to treat hospitalized patients with severe COVID-19. The oral XPO1...
...is approved at higher doses to treat patients with relapsed or refractory multiple myeloma. Because XPO1...
...https://www.biocentury.com/coronavirus . Targets NCR1 (NKP46; CD335) - Natural cytotoxicity triggering receptor 1 XPO1 (CRM1) - Exportin 1 Elizabeth...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

...combinations. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) plans to submit an sNDA next quarter for the oral XPO1...
...in the second-line setting with Velcade or other proteasome inhibitors. Xpovio is the only marketed XPO1...
...and Jefferies. Targets XPO1 (CRM1) - Exportin 1 Sandi Wong, Assistant Editor Velcade, bortezomib (LDP-341, MLN341, PS-341) Karyopharm Therapeutics Inc. Exportin 1 (XPO1) (CRM1)...
BioCentury | Feb 19, 2020
Regulation

Regulatory Roundup: Priority Review for Xpovio, Tecentriq in new indications; plus CRLs delay Keytruda dosing update

...PDUFA date is June 23. Xpovio is an oral selective inhibitor of nuclear export protein XPO1...
...death 1 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 XPO1 (CRM1) - Exportin 1 Paul...
BioCentury | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

Novartis is pivoting away from internal development of CAR Ts in solid tumors, it said Thursday at its R&D day. The company is, however, pressing forward with the modality via partnerships, and plans to use...
BioCentury | Aug 2, 2019
Company News

Management tracks: Third Rock-backed Thrive names new CEO; plus PhRMA, Adverum and more

Thrive Earlier Detection Corp. (Cambridge, Mass.) said David Daly will succeed Steve Kafka as CEO, effective Aug. 19. Daly was chief commercial officer of the Foundation Medicine Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Kafka is...
BioCentury | Jul 3, 2019
Company News

After negative panel vote, FDA approves Karyopharm's multiple myeloma drug

...Selinexor's Benefit" ). Xpovio is an oral selective inhibitor of nuclear export protein exportin 1 (XPO1; CRM1...
Items per page:
1 - 10 of 134